Market Overview

Morgan Stanley: Global Blood Therapeutics 'Clearly Encouraged' By Sickle Cell Therapy Data

Morgan Stanley: Global Blood Therapeutics 'Clearly Encouraged' By Sickle Cell Therapy Data
Related GBT
48 Biggest Movers From Friday
The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
Stocks With Rising Relative Price Strength: Global Blood Therapeutic (Investor's Business Daily)

Global Blood Therapeutics Inc (NASDAQ: GBT), a clinical-stage biopharmaceutical company that focuses on treating blood-based disorders, released results from multiple data presentations during the 59th American Society of Hematology Annual Meeting & Exposition.

The Analyst

Morgan Stanley's Matthew Harrison maintains an Overweight on Global Blood's stock with an unchanged $55 price target.

The Thesis

Global Blood's interim data for its Phase 2a trial of the sickle cell disease therapy GBT440 in adolescents was consistent with prior adult results and demonstrates efficacy on top of hydroxyurea and utility of the PRO, Harrison said in a Sunday note. (See Harrison's track record here.) 

Among the 11 patients with available efficacy data through 16 weeks, six of them achieved increased hemoglobin of greater than 1 g/dL and the median hemoglobin change was 1.1 g/dL, according to Morgan Stanley. There was also a reduction in daily symptoms among 10 of the 12 patients as measured by the total symptom score, or TSS. In fact, five of the 12 patients saw their TSS decline to zero as measured by the PRO.

After meeting with the company's management team, Harrison said the executives were "clearly encouraged" by the data. In addition, the company plans to update investors on the validation of the PRO and provide a quantitative measure of clinical utility based on the PRO.

"Investors seemed focused on the potential correlation of the PRO with hemoglobin response, but management cautioned that in such a small dataset any views were just anecdotal," the analyst said. "Investors also focused on other factors which could influence the PRO, such as pain medication. Management suggested randomization would mitigate this concern."

Price Action

Shares of Global Blood were trading lower by 10.28 percent at $41 Monday morning. 

Related Links:

Global Blood Therapeutics Demonstrates 'Compelling Potential' In Sickle Cell Treatment

Global Blood Therapeutics' Acquisition Value Could Be At Least $3 Billion

Photo by Dr. Graham Beards/Wikimedia. 

Latest Ratings for GBT

Dec 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Aug 2018PiperJaffrayInitiates Coverage OnOverweight
Aug 2018WedbushMaintainsOutperformOutperform

View More Analyst Ratings for GBT
View the Latest Analyst Ratings

Posted-In: ASH Blood DisordersAnalyst Color Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga


Related Articles (GBT)

View Comments and Join the Discussion!

Latest Ratings

ADIMorgan StanleyDowngrades0.0
ALKSGoldman SachsDowngrades26.0
BHGECredit SuisseUpgrades25.0
BLMNMorgan StanleyUpgrades0.0
OKTADA DavidsonInitiates Coverage On62.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Celgene's Lymphoma Strategy Is Its Biggest Positive, Analyst Says

This Day In Market History: Bernie Madoff Arrested